Clinical Trial Update: Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

Phase 1 dose-finding study of GSK2636771 in combination with enzalutamide in metastatic castration-resistant prostate cancer completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)
• GSK2636771

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2020-10-22